Loading asset research
Acumen Pharmaceuticals Inc. Common Stock
ABOSNasdaq · USD · StocksQuote as of · Exchange session not verified$2.92
+2.10%
Today
ABOS
Loading 1D prices…
Market cap
$211.2M
Volume
318.2K
52w high
$3.6052w low
$1.21Company profile
Acumen Pharmaceuticals Inc. Common Stock
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Newton, MA, United States
Employees
60
Fiscal year end
1231
CIK
1576885
Session & valuation
Open$2.93
Previous close$2.86
Day high$2.98
Day low$2.84
30-day avg. volume347.5K
Outstanding shares72.3M
Diluted EPS-$2.00
Latest annual period
P/E (trailing)-1.46
P/E (forward)-2.04
Price / book3.69
Beta0.38
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| PLXProtalix BioTherapeutics Inc. (DE) Common Stock | $212.7M | $52.7M | -12.52% | -$0.08 | -3.30% | Buy |
| IPHAInnate Pharma S.A. ADS | $208.9M | — | — | -$0.55 | -0.53% | Buy |
| CHRSCoherus Oncology Inc. Common Stock | $205.5M | $42.2M | +398.43% | $1.43 | +0.00% | Buy |
| ARMPArmata Pharmaceuticals Inc. Common Stock | $200M | $0.00 | — | -$4.80 | +2.87% | Buy |
| SRZNSurrozen Inc. Common Stock | $223.3M | $3.5M | -6960.77% | -$32.37 | -2.31% | Buy |